財団法人癌研究会癌化学療法センター分子薬理部部長の矢守隆夫氏らは、全薬工業と共同で開発した経口で毒性も低く効果のあるPI3キナーゼ阻害剤ZSTK474の詳細をこのほど明らかにした。 PI3キナーゼは発がんやがんの生存、増殖、転移などに重要な役割を ...

日経メディカルOncologyニュース 連載をフォロー PI3キナーゼ阻害薬taselisibが日本人の固形癌、乳癌にも有用である可能性【SABCS2015】 2015/12/11 横山勇生 癌 ...

Scientists have developed a new drug which can reduce the growth of tumours* in mice by up to 98 per cent, according to a study published in Molecular Cancer Therapeutics** this week. In this study, ...

In 1987 I attended a meeting at Cold Spring Harbor on phosphatidylinositol signaling that turned out to be pivotal for me. A few years earlier I'd helped show that a phosphatidylinositol (PI) kinase ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, ...